Growth hormone receptor (GHR) Human siRNA Oligo Duplex (Locus ID 2690)
CAT#: SR301794
GHR (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
CNY 4,090.00
货期*
4周
规格
Cited in 5 publications. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_000163, NM_001242399, NM_001242400, NM_001242401, NM_001242402, NM_001242403, NM_001242404, NM_001242405, NM_001242406, NM_001242460, NM_001242461, NM_001242462 |
Synonyms | GHBP; GHIP |
Components | GHR (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2690)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | This gene encodes a member of the type I cytokine receptor family, which is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to receptor dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature. In humans and rabbits, but not rodents, growth hormone binding protein (GHBP) is generated by proteolytic cleavage of the extracellular ligand-binding domain from the mature growth hormone receptor protein. Multiple alternatively spliced transcript variants have been found for this gene.[provided by RefSeq, Jun 2011] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (5)
The use of this RNAi has been cited in the following citations: |
---|
Growth Hormone Upregulates Mediators of Melanoma Drug Efflux and Epithelial-to-Mesenchymal Transition In Vitro and In Vivo
,Qian, Y;Basu, R;Mathes, SC;Arnett, NA;Duran-Ortiz, S;Funk, KR;Brittain, AL;Kulkarni, P;Terry, JC;Davis, E;Singerman, JT;Henry, BE;List, EO;Berryman, DE;Kopchick, JJ;,
Cancers
,PubMed ID 33291663
[GHR]
|
Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma
,Basu, R;Kulkarni, P;Qian, Y;Walsh, C;Arora, P;Davis, E;Duran-Ortiz, S;Funk, K;Ibarra, D;Kruse, C;Mathes, S;McHugh, T;Brittain, A;Berryman, DE;List, EO;Okada, S;Kopchick, JJ;,
Cancers (Basel) 2019
,PubMed ID 31547367
[GHR]
|
TITLE: Growth hormone receptor (GHR) knockdown sensitizes human melanoma cells to chemotherapy by attenuating expression of ABC drug efflux pumps
,Basu, R;Baumgaertel, N;Wu, S;Kopchick, JJ;,
researchgate.net
,PubMed ID 28293855
[GHR]
|
Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways
,Basu, R;Wu, S;Kopchick, JJ;,
Oncotarget
,PubMed ID 28223541
[GHR]
|
Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma
,null,
Experimental & Molecular Medicine
,PubMed ID 25301264
[GHR]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...